Allulose, a low-calorie sugar substitute, has gained popularity among diabetics for its sweetening properties without significantly impacting blood sugar levels. However, its regulatory status varies across different countries, affecting its availability and use. For individuals managing diabetes, understanding the legal status of allulose in their region is essential for making informed dietary choices. This article provides a comprehensive overview of allulose regulation worldwide, explores its safety profile, and offers practical guidance for diabetic consumers navigating this emerging sweetener.

What Is Allulose?

Allulose, also known as D-psicose, is a rare sugar naturally present in tiny quantities in fruits such as figs, raisins, and jackfruit, as well as in maple syrup and molasses. Chemically, it is an epimer of fructose—meaning it shares the same molecular formula (C₆H₁₂O₆) but differs in the arrangement of atoms. This slight structural change gives allulose about 70% of the sweetness of sucrose (table sugar) while providing only 0.2 to 0.4 calories per gram, compared to 4 calories per gram for sugar.

The key feature that makes allulose attractive to diabetics is its metabolic pathway. Unlike glucose or fructose, allulose is absorbed by the small intestine but is not metabolized into energy. Instead, it is excreted largely unchanged in the urine. As a result, it does not raise blood glucose or insulin levels, making it a virtually zero-glycemic sweetener. Furthermore, early research suggests allulose may even improve glycemic control by inhibiting glucose absorption and enhancing insulin sensitivity, though more human studies are needed.

Commercial production of allulose typically involves enzymatic conversion from corn or wheat starch. The starch is broken down into glucose, which is then isomerized into allulose using a specific enzyme derived from microorganisms. This process yields a crystalline powder that can be used in a wide range of foods and beverages, from baked goods and ice cream to soft drinks and tabletop sweeteners.

Regulatory Status in the United States

In the United States, the Food and Drug Administration (FDA) has taken a relatively progressive stance. The FDA has not approved allulose as a food additive but has issued multiple generally recognized as safe (GRAS) notifications for allulose. Since 2012, several companies have submitted GRAS notices, and the FDA has not objected to these determinations, effectively permitting the use of allulose in food products without premarket approval.

One of the most significant regulatory actions occurred in 2020, when the FDA issued a guidance document stating that allulose does not need to be declared as a "sugar" on the Nutrition Facts label. Instead, it may be listed as a separate carbohydrate, helping consumers differentiate it from added sugars. This labeling flexibility is particularly beneficial for diabetics who monitor sugar intake. Additionally, allulose can be counted as a sugar alcohol for some labeling purposes, but technically it is not a sugar alcohol—it is a rare sugar.

The FDA's GRAS status for allulose applies to its use in a wide range of food categories, including baked goods, beverages, candy, dairy products, frozen desserts, and sauces. Manufacturers are required to follow good manufacturing practices, but no specific usage limits have been set. As of 2024, allulose is widely available in U.S. supermarkets in both bulk and product forms. You can verify the FDA's stance by reviewing the FDA GRAS Notice Inventory (search for "allulose" or "psicose").

FDA Labeling Considerations for Diabetics

Because allulose is not fully absorbed, the FDA allows manufacturers to subtract most of its carbohydrates from the total carb count. For diabetics counting net carbs, this is a major advantage. However, the FDA recommends that products containing allulose still list it in the ingredients and on the Nutrition Facts panel under "Total Carbohydrate." Always read labels carefully, as some products may combine allulose with other sweeteners that do affect blood sugar.

Regulatory Status in the European Union

The European Union (EU) has taken a markedly more cautious approach. Under the Novel Foods Regulation (EU Regulation 2015/2283), any food ingredient not consumed to a significant degree before 1997 must undergo a rigorous safety assessment before authorization. Allulose is classified as a novel food, and as of mid-2024, no application has received full approval from the European Food Safety Authority (EFSA).

Several companies have submitted novel food applications for allulose over the past five years, but EFSA has repeatedly requested additional data on safety, particularly regarding its effects on the gastrointestinal system and metabolic outcomes. In 2023, EFSA issued a scientific opinion concluding that allulose, at the intended use levels, did not raise major safety concerns, but the assessment is still ongoing. Consequently, allulose is not yet permitted for sale as a food ingredient in EU member states. Products containing allulose that were imported or manufactured before the regulation are considered non-compliant and can be removed from the market.

For EU residents with diabetes, this means that allulose is currently unavailable in most grocery stores and online retailers within the bloc. Some specialty importers may offer it, but consumers should be aware that such products may be operating in a legal gray area. It is advisable to consult with healthcare providers and check with the European Commission for updates on novel food approvals. You can track the status of allulose applications on the European Commission Novel Food Catalogue (currently not listed).

Future Prospects in the EU

Given the growing demand for low-calorie sweeteners and the positive safety data from other regions, it is likely that allulose will gain EU authorization within the next two to three years. Until then, diabetics in the EU may consider alternative sweeteners such as stevia, monk fruit, or erythritol, which are already approved and widely available.

Regulatory Status in Japan

Japan has long been a pioneer in allulose regulation. The country's Ministry of Health, Labour and Welfare (MHLW) recognized allulose as a food ingredient in the early 2000s, and it is now classified as a specialty sweetener. Unlike the EU, Japan does not require premarket approval for novel foods; instead, it evaluates ingredients under the "Food for Specified Health Uses" (FOSHU) system and general food regulations.

Allulose is permitted for use in virtually all food categories, including beverages, confectionery, dairy, and bakery products. Japanese manufacturers often market products containing allulose as "sugar-free" or "low-glycemic," and the sweetener is widely adopted in health-oriented foods. In fact, Japan was one of the first countries to commercialize allulose as a tabletop sweetener under the brand name "Psicose." The Japanese government has also funded research into allulose's metabolic benefits, further supporting its safe use.

For diabetics living in Japan, allulose is easily accessible in supermarkets and drugstores. The labeling regulations require that allulose be listed in the ingredients, but it is not counted as sugar on the nutrition panel. Because Japan's food regulatory framework is less bureaucratic than the EU's, allulose products have been available for over a decade, providing a rich history of safe consumption. Visitors or expatriates with diabetes should have no trouble finding allulose-sweetened products.

Regulatory Status in Other Countries

The regulatory landscape for allulose continues to evolve globally. Below is a detailed look at several key nations and regions.

Canada

Health Canada has shown openness to allulose through a Temporary Marketing Authorization Letter (TMAL) process. In 2022, Health Canada issued a TMAL allowing the use of allulose as a food ingredient in products such as beverages, baked goods, and dairy, pending a full safety review. The authorization includes specific labeling requirements: allulose must be declared on the ingredient list and cannot be labeled as "sugar" or "added sugar." As of 2024, Health Canada has not finalized permanent regulations, but allulose is legally available in Canada under the TMAL. Diabetics should look for products that explicitly state "allulose" on the label. More information is available via Health Canada's TMAL page (search for "allulose").

Australia and New Zealand

Food Standards Australia New Zealand (FSANZ) approved allulose as a novel food in 2020 through Amendment 192 to the Food Standards Code. The approval permits allulose in a range of foods, including breakfast cereals, confectionery, desserts, and soft drinks, at maximum use levels. Importantly, FSANZ requires that any claims regarding glycemic impact be substantiated, and allulose must be listed as an ingredient. Products containing allulose are now appearing in major Australian supermarkets. For diabetics, this means allulose is legally available and can be used as a sugar substitute, though it is not as widespread as in the U.S. or Japan.

China

China's National Health Commission (NHC) has progressively recognized allulose as safe. In 2019, allulose was approved as a food additive (sweetener) under the Chinese national food safety standard GB 2760. It is permitted in a variety of food categories, including beverages, ice cream, and dairy. Chinese manufacturers have begun producing allulose domestically, making it increasingly available in domestic markets. However, labeling regulations require it to be listed as "allulose" or "psicose," and it is not counted as sugar for nutritional purposes. Diabetics in China can find allulose in health food stores and online platforms.

South Korea

The Ministry of Food and Drug Safety (MFDS) approved allulose as a food ingredient in 2015, classifying it as a sugar substitute. South Korea allows its use in foods such as beverages, candy, and jam. As in Japan, allulose is widely available and marketed for its low glycemic index. Korean regulations require that allulose be listed in the ingredient list, but it is exempt from sugar declarations.

Mexico and Latin America

In Mexico, the Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has not issued a specific regulation for allulose, but it is generally allowed as a food additive if it meets CODEX standards. Many allulose-sweetened products from the U.S. are imported and sold in Mexico, particularly in urban areas. Other Latin American countries such as Brazil and Argentina are also showing interest; Brazil's ANVISA is currently evaluating allulose as a novel food. Diabetics in the region should check with local health authorities before purchasing products containing allulose.

Implications for Diabetics

For individuals living with diabetes, the regulatory status of allulose directly impacts its safety, availability, and labeling. In countries where it is approved, allulose offers a zero-glycemic sweetening option that does not require insulin for metabolism. Clinical studies have shown that allulose does not raise postprandial blood glucose or insulin levels, and some evidence suggests it may even improve glucose tolerance over time.

However, there are important considerations. Because allulose is not fully absorbed, consuming large amounts (more than 15-30 grams per day) may cause gastrointestinal side effects such as bloating, gas, and abdominal discomfort. These effects are similar to those of sugar alcohols like erythritol and sorbitol. Diabetics should start with small amounts to assess tolerance.

Another practical implication is that even in approved countries, not all products labeled "sugar-free" or "low-calorie" use allulose. Some may combine allulose with other sweeteners like stevia or monk fruit for taste balance. Diabetics must read the ingredient list carefully and check the nutrition panel for total carbohydrates and added sugars.

Tips for Diabetics Choosing Allulose Products

  • Check local regulatory status: Ensure allulose is approved in your country before purchasing. If it is not approved, consider alternatives such as stevia, monk fruit, or erythritol.
  • Look for certified products: In the U.S., look for products with a GRAS notice; in Australia, check for FSANZ approval; in Japan, trust the FOSHU or "food for specified health uses" seal.
  • Monitor portion sizes: Even though allulose does not spike blood sugar, excessive intake may lead to gastrointestinal discomfort.
  • Pair with a balanced diet: Allulose is not a magic bullet. It should be part of a comprehensive diabetes management plan that includes whole foods, fiber, and exercise.
  • Consult a healthcare provider: Before adding new sweeteners, especially if you have type 1 diabetes or insulin resistance, discuss with your endocrinologist or dietitian.

Comparative Overview: Allulose vs. Other Sweeteners

To help diabetics make informed choices, the table below contrasts allulose with common alternative sweeteners.

Sweetener Calories per Gram Glycemic Impact Regulatory Status (US/EU/Japan) Common Side Effects
Allulose 0.2-0.4 Near zero GRAS (US), not approved (EU), approved (Japan) Bloating at high doses
Erythritol 0.24 Zero GRAS (US), approved (EU), approved (Japan) GI upset, digestive discomfort
Stevia 0 Zero GRAS (US), approved (EU), approved (Japan) Bitter aftertaste for some
Monk fruit 0 Zero GRAS (US), approved (EU), approved (Japan) Less common; may have slight aftertaste
Aspartame 4 Negligible in small amounts Approved (US, EU, Japan) Phenylketonuria risk; headache in sensitive individuals

Allulose stands out for its sugar-like taste and texture without the bitter aftertaste of stevia or the cooling effect of erythritol. However, its regulatory limitations in the EU and initial gastrointestinal side effects are drawbacks. Diabetics who can legally access allulose often prefer it for baking because it browns and caramelizes similarly to sucrose.

Future Outlook for Allulose Regulation Worldwide

The global trend toward low-calorie, natural sweeteners is likely to drive regulatory expansions for allulose. Several factors point toward increased approvals:

  • Ongoing clinical research: Studies continue to investigate allulose's metabolic benefits, including its potential to reduce liver fat and improve glycemic control. As evidence accumulates, regulators may lower safety hurdles.
  • Consumer demand: Multinational food companies are investing in allulose product lines, increasing pressure on regulators like EFSA to expedite approvals.
  • Trade agreements: As more countries adopt favorable regulations, harmonization through bodies like the Codex Alimentarius may standardize labeling and safety assessments.

In the EU, a decision on allulose's novel food application could come as early as 2025. Should EFSA issue a positive opinion, the European Commission would authorize it, opening the market to millions of diabetic consumers. Similarly, Health Canada is expected to finalize its temporary authorization within the next few years. For diabetics in currently restrictive regions, the wait may soon be over.

Conclusion

The regulatory status of allulose varies dramatically across the globe, reflecting differing approaches to novel food safety and consumer protection. In the United States, Japan, Australia, South Korea, and Canada, allulose is legally available and widely used as a low-calorie, zero-glycemic sweetener suitable for diabetics. In the European Union and several other regions, allulose remains unavailable while regulators evaluate its safety.

For diabetics, the key is to stay informed about local regulations and to choose sweeteners that are both safe and effective for blood glucose management. Allulose, where approved, offers an excellent alternative to sugar without the metabolic consequences. However, it is not a magic solution—individual tolerance varies, and it should be used as part of a balanced diet. As research and regulations evolve, allulose is poised to become a mainstream option for diabetes-friendly sweetening worldwide.